Envestnet Asset Management Inc. Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Envestnet Asset Management Inc. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.4% during the second quarter, HoldingsChannel reports. The firm owned 103,422 shares of the biopharmaceutical company’s stock after selling 13,305 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $54,292,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Private Trust Co. NA grew its position in Regeneron Pharmaceuticals by 13.1% in the 1st quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 19 shares during the last quarter. Proficio Capital Partners LLC lifted its stake in shares of Regeneron Pharmaceuticals by 6.2% in the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock worth $207,000 after acquiring an additional 19 shares during the period. Cove Private Wealth LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 4.5% in the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 20 shares in the last quarter. Marino Stram & Associates LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 5.3% in the second quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 20 shares in the last quarter. Finally, Activest Wealth Management increased its stake in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity

In other news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Down 0.3%

REGN opened at $651.80 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The company has a market cap of $69.08 billion, a price-to-earnings ratio of 15.61, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $883.15. The business’s fifty day moving average is $581.80 and its two-hundred day moving average is $565.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the previous year, the company posted $12.46 EPS. The business’s revenue was up .9% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Analysts Set New Price Targets

A number of brokerages recently commented on REGN. Sanford C. Bernstein raised their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research report on Wednesday, August 27th. Wall Street Zen raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, October 23rd. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a “buy” rating and a $890.00 price objective for the company. Finally, Redburn Atlantic upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $802.36.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.